Not your mother's hormone therapy: Highly selective estrogen receptor beta agonists as next-generation therapies for menopausal symptom relief.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic rationale, preclinical animal findings, and prior clinical trials.
PubMed 40482564 · doi:10.1016/j.yhbeh.2025.105773
What was done
This narrative review summarizes the history of menopausal hormone therapy and outlines the neurobiological mechanisms through which estrogens regulate memory dysfunction and hot flashes, focusing on estrogen receptor beta (ERβ). It evaluates past and current clinical trials alongside preclinical evidence examining synthetic, highly selective ERβ agonists in mouse models of ovarian hormone loss and Alzheimer's disease.
What was found
The abstract reports no quantitative data or effect sizes. Preclinical findings described indicate that a highly potent and selective synthetic ERβ agonist improved object recognition and spatial memory, and decreased drug-induced hot flashes in mouse models without the adverse effects associated with non-selective estrogen therapy.
Why it matters
Selective ERβ targeting represents a potential strategy to treat menopausal vasomotor symptoms and cognitive complaints while avoiding the oncologic and cardiovascular risks linked to traditional non-selective estrogen therapies.
Limits
No human quantitative outcome data, sample sizes, or formal systematic review methodologies are reported in the abstract. Key findings rely heavily on animal models of ovarian hormone deprivation and Alzheimer's disease, which may not translate directly to human clinical efficacy or safety.
Cited by
- context A large number of the side effects and symptoms of menopause are caused by the loss of estrogen receptor beta (ERβ) activation.